Prostate Cancer Diagnostics Market Size, Share, Report 2024-2033
The global prostate cancer diagnostics market was estimated at USD 9.13 billion in 2023 and it is expected to surpass around USD 17.06 billion by 2033, poised to grow at a CAGR of 6.45% from 2024 to 2033. The global prostate cancer diagnostics Market is witnessing substantial growth, driven by advancements in diagnostic technologies, rising awareness about early detection, and an increasing prevalence of prostate cancer worldwide
The growth of the prostate cancer diagnostics Market is propelled by several key factors. Technological advancements play a pivotal role, with ongoing innovations in diagnostic tools such as liquid biopsy, MRI imaging, and genomic testing contributing to more accurate and early detection of prostate cancer. The escalating global prevalence of prostate cancer, driven by factors like an aging population and lifestyle changes, underscores the increasing demand for diagnostic solutions. Growing awareness campaigns emphasizing the significance of regular screening for prostate cancer also significantly contribute to market expansion. Supportive government policies and initiatives, aimed at cancer prevention and early detection, further boost the accessibility of diagnostic tools. In this competitive landscape, where key players invest in research and development, strategic collaborations, mergers, and acquisitions play a crucial role in enhancing market presence. Overall, the convergence of technological advancements, rising prevalence, and increased awareness positions the prostate cancer diagnostics market for sustained growth in the foreseeable future.
| Report Coverage | Details |
| Market Revenue by 2033 | USD 17.06 billion |
| Growth Rate from 2024 to 2033 | CAGR of 6.45% |
| Revenue Share of North America in 2023 | 45% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
The Confirmatory Tests segment held the largest revenue share of 67% in 2023. The increasing incidence of prostate cancer spreading to other organs, particularly in cases of genital and urinary tract infections in the U.S., has been a contributing factor. According to a May 2022 article from the American Cancer Society, abnormal results in post-preliminary testing, including PSA and digital rectal exam (DRE), necessitate patients to undergo various confirmatory tests for an accurate diagnosis of prostate cancer. In instances where the cancer has extended to other organs, imaging tests are conducted to assess the risk of metastasis.
The Preliminary Tests segment is poised for significant market growth in the forecast period, driven by the increasing prevalence of prostate cancer. As highlighted in a November 2022 article by the American Cancer Society, the widespread availability of PSA screening has played a crucial role in enabling early diagnosis and treatment, consequently improving survival rates. PSA tests are capable of detecting small and unrecognized tumors, potentially preventing their progression to an advanced cancer stage.
In 2023, the Adenocarcinoma segment dominated the market, holding the largest revenue share. Patients diagnosed with Adenocarcinoma of the prostate commonly experience symptoms such as difficulty urination, a weak stream, occasional hematuria, incomplete bladder emptying, and chronic back pain. Clinical examinations often reveal an enlarged prostate and abnormal findings in digital rectal exams (DRE), though these exhibit low specificity and sensitivity. Notably, an NCBI article from June 2022 highlighted that Adenocarcinoma of the Prostate ranks as the second most common cancer in men globally and is the third leading cause of death in the U.S. The decline in prostate cancer mortality, especially in the U.S., is attributed to increased screening practices and the utilization of adjuvant therapies.
The Interstitial Cell Carcinoma (ICC) segment is projected to achieve a noteworthy CAGR over the forecast period. In contrast to the more prevalent adenocarcinoma, ICC originates from interstitial cells, presenting challenges in both diagnosis and management. According to an NCBI article from August 2022, advanced imaging techniques, such as multiparametric MRI, play a crucial role in accurately detecting and characterizing ICC lesions within the prostate. The treatment of interstitial cell carcinoma often necessitates a personalized approach, exploring targeted therapies that address specific molecular markers associated with ICC to enhance efficacy while minimizing adverse effects.
In 2023, the Outpatient Facilities segment took the lead in revenue, holding the largest share. Outpatient facilities offer distinct advantages over other healthcare options, primarily due to a significant reduction in hospital-related expenses, including admission costs and other hospitality-related charges. The substantial share of the outpatient segment can be attributed to its cost-effectiveness, increased service availability, and the convenience it provides to patients. The focus on cost efficiency and improved accessibility underscores the dominance of this segment, aligning with a healthcare trend that prioritizes economic effectiveness and patient convenience.
The Hospitals segment is projected to register a noteworthy CAGR over the forecast period. Hospitals play a pivotal role in the diagnosis, treatment, and care of prostate cancer patients. Serving as central hubs for prostate cancer management, hospitals offer a comprehensive range of services, from initial screening to advanced treatments and supportive care. For hospitals, the investment in state-of-the-art diagnostic technologies is crucial. Advanced imaging modalities, such as multiparametric MRI, contribute to accurate diagnosis and enhance treatment planning.
In 2023, North America region dominated the market with the largest market share of 45%. This leadership is attributed to factors such as heightened patient awareness, an increasing prevalence of prostate cancer, proactive government measures, continuous technological advancements, and improvements in healthcare infrastructure. As per a January 2022 article from the American Cancer Society, prostate cancer tends to have a higher incidence in older men, especially those aged over 65, with rare cases reported in individuals under 40. Approximately 10 out of 6 cases are typically diagnosed in men over 65.
The Asia Pacific region is poised to witness the fastest growth in the market. As indicated by a July 2022 article from Informa UK Limited, prostate cancer demonstrates varying incidence rates between countries with very high Human Development Index (HDI), such as Japan and China, and those with lower HDI, like Vietnam and the Philippines. Notably, there has been a noticeable surge in prostate cancer cases in both high and low HDI countries, including the Philippines, Japan, China, and Singapore. This increase in incidence is attributed to the heightened adoption of prostate-specific antigen (PSA) screening in these regions.
By Test Type
By Type
By End Use
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Test Type Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Prostate Cancer Diagnostics Market
5.1. COVID-19 Landscape: Prostate Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Prostate Cancer Diagnostics Market, By Test Type
8.1. Prostate Cancer Diagnostics Market, by Test Type, 2024-2033
8.1.1 Preliminary Tests
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Confirmatory Tests
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Prostate Cancer Diagnostics Market, By Type
9.1. Prostate Cancer Diagnostics Market, by Type, 2024-2033
9.1.1. Adenocarcinoma
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Interstitial Cell Carcinoma
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Other
9.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Prostate Cancer Diagnostics Market, By End Use
10.1. Prostate Cancer Diagnostics Market, by End Use, 2024-2033
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Outpatient Facilities
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Home Care
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Research & Manufacturing
10.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Prostate Cancer Diagnostics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Type (2021-2033)
11.1.3. Market Revenue and Forecast, by End Use (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Type (2021-2033)
11.1.4.3. Market Revenue and Forecast, by End Use (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Type (2021-2033)
11.1.5.3. Market Revenue and Forecast, by End Use (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.2.2. Market Revenue and Forecast, by Type (2021-2033)
11.2.3. Market Revenue and Forecast, by End Use (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Type (2021-2033)
11.2.4.3. Market Revenue and Forecast, by End Use (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Type (2021-2033)
11.2.5.3. Market Revenue and Forecast, by End Use (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Type (2021-2033)
11.2.6.3. Market Revenue and Forecast, by End Use (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Type (2021-2033)
11.2.7.3. Market Revenue and Forecast, by End Use (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.3.2. Market Revenue and Forecast, by Type (2021-2033)
11.3.3. Market Revenue and Forecast, by End Use (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Type (2021-2033)
11.3.4.3. Market Revenue and Forecast, by End Use (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Type (2021-2033)
11.3.5.3. Market Revenue and Forecast, by End Use (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Type (2021-2033)
11.3.6.3. Market Revenue and Forecast, by End Use (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Type (2021-2033)
11.3.7.3. Market Revenue and Forecast, by End Use (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.4.2. Market Revenue and Forecast, by Type (2021-2033)
11.4.3. Market Revenue and Forecast, by End Use (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Type (2021-2033)
11.4.4.3. Market Revenue and Forecast, by End Use (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Type (2021-2033)
11.4.5.3. Market Revenue and Forecast, by End Use (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Type (2021-2033)
11.4.6.3. Market Revenue and Forecast, by End Use (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Type (2021-2033)
11.4.7.3. Market Revenue and Forecast, by End Use (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.5.2. Market Revenue and Forecast, by Type (2021-2033)
11.5.3. Market Revenue and Forecast, by End Use (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Type (2021-2033)
11.5.4.3. Market Revenue and Forecast, by End Use (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Type (2021-2033)
11.5.5.3. Market Revenue and Forecast, by End Use (2021-2033)
Chapter 12. Company Profiles
12.1. MDx Health.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Myriad Genetics, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Abbott Laboratories.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffman-La Roche AG.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer AG.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Siemens Healthcare GmbH
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. OPKO Health, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Genomic Health.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Pfizer Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers